Akebia Therapeutics Inc To Discuss The Response To The FDRR Transcript
Good day, and thank you for standing by. Welcome to the Akebia Corporate Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.
And I would now like to hand the conference over to your speaker today, Ms. Mercedes Carrasco, Senior Director, Investor and Corporate Communications. Ms. Carrasco, please go ahead.
Thank you, Chris. Welcome, and thank you for joining the call this morning.
Today, Akebia announced that we have received a written response from the Office of New Drugs of the FDA regarding our formal dispute resolution regarding the complete response letter received in March 2022 for vadadustat. Today, we will discuss the response, next steps in the regulatory process and provide a general business update related to vadadustat.
Please note that a press release was issued earlier today, Tuesday, May 30, detailing the response, and that release is available on the Investors section of our website.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |